Tape-strips provide a minimally invasive approach to track therapeutic response to topical corticosteroids in atopic dermatitis patients

Publication date: Available online 2 September 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Caroline Meyer Olesen, Ana B. Pavel, Jianni Wu, Daniela Mikhaylov, Ester Del Duca, Yeriel Estrada, James G. Krueger, Ning Zhang, Maja-Lisa Clausen, Tove Agner, Emma Guttman-Yassky
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research

Related Links:

This study will also provide supportive evidence to that provided by currently ongoing studies on the efficacy and safety of sarilumab in this clinical context.Trial designA phase two multi-center randomised controlled trial (RCT) with two parallel arms (1:1 ratio).ParticipantsThey will be hospitalized patients, of at least 18 years of age, with severe COVID-19 who have positive RT-PCR test and have radiographic evidence of pulmonary infiltrates by imaging or rales/crackles on exam and SpO2 ≤ 94% on room air that requires supplemental oxygen. Patients must present elevation of inflammatory parameters (IL-6> 40 pg/mL ...
Source: Trials - Category: Research Source Type: clinical trials
Baricitinib may provide another treatment option for patients with atopic dermatitis who did not adequately respond to corticosteroid therapy.The British Journal of Dermatology
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Dermatology Journal Article Source Type: news
Publication date: Available online 2 September 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Caroline Meyer Olesen, Ana B. Pavel, Jianni Wu, Daniela Mikhaylov, Ester Del Duca, Yeriel Estrada, James G. Krueger, Ning Zhang, Maja-Lisa Clausen, Tove Agner, Emma Guttman-Yassky
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
CONCLUSION: With proper treatment, nummular eczema can be cleared over a few weeks, although the course can be chronic and characterized by relapses and remissions. Moisturizing of the skin and avoidance of identifiable exacerbating factors such as hot water baths and harsh soaps may reduce the frequency of recurrence. Diseases that present with annular lesions may mimic nummular eczema and the differential diagnosis is broad. As such, physicians must be familiar with this condition so that an accurate diagnosis can be made, and appropriate treatment initiated. PMID: 32778043 [PubMed - as supplied by publisher]
Source: Recent Patents on Inflammation and Allergy Drug Discovery - Category: Allergy & Immunology Tags: Recent Pat Inflamm Allergy Drug Discov Source Type: research
AbstractPurpose of reviewA variety of skin diseases are associated with impaired barrier function. The crucial pillars in therapy of previously mentioned conditions are avoidance of triggers, skin protection and individually adapted medical therapy. Until recently, besides of topical corticosteroids, the treatment options were limited. However, a variety of new therapies of skin barrier-related skin diseases became available over the last years. Our goal was to investigate new findings and treatment options in skin diseases with barrier dysfunction, emphasizing on contact dermatitis, hand eczema and atopic dermatitis.Recen...
Source: Current Treatment Options in Allergy - Category: Allergy & Immunology Source Type: research
We report this consensus to support allergists and clinical immunologists to make optimal decisions under the urgent situation in Asia. PMID: 32638559 [PubMed]
Source: Allergy, Asthma and Immunology Research - Category: Allergy & Immunology Tags: Allergy Asthma Immunol Res Source Type: research
AbstractAtopic dermatitis (AD) is generally considered a T helper type 2 –dominated disease. Pediatric AD is usually less severe than adult AD, but it may present as moderate to severe lesions that are inadequately managed by current modalities including emollients/moisturizers, topical corticosteroids (TCSs), topical calcineurin inhibitors (TCIs), and even systemic im munosuppressants (such as cyclosporine, azathioprine, methotrexate, and mycophenolate mofetil). In addition, systemic immunosuppressants are often not recommended for childhood AD by the current guidelines due to their toxicities. Therefore, there is s...
Source: Clinical Reviews in Allergy and Immunology - Category: Allergy & Immunology Source Type: research
Purpose of review This review reports on published clinical studies (full publications) with novel therapeutic agents on the treatment of atopic dermatitis with a focus on the last 2 years. Recent findings Atopic dermatitis is a T-cell driven complex inflammatory skin disease. The secretion of cytokines involving not only particularly Th2 but also Th17 and Th22 cell subsets provides a broad spectrum of potential therapeutical targets. A couple of studies on atopic dermatitis with new therapeutical antibodies that target not only the Th2 cytokines IL-4, IL-13, IL- 31 but also additional targets, such as TSLP, IL-22 or ...
Source: Current Opinion in Allergy and Clinical Immunology - Category: Allergy & Immunology Tags: SKIN ALLERGY: Edited by Thomas Werfel and Torsten Zuberbier Source Type: research
CONCLUSION: All patients were misdiagnosed as AD exacerbation. Therefore, EH should be considered in the differential diagnosis of AD exacerbation especially in the infants with moderate to severe AD. PMID: 32558432 [PubMed - in process]
Source: The Turkish Journal of Pediatrics - Category: Pediatrics Authors: Tags: Turk J Pediatr Source Type: research
Date: June 15, 2020 Issue #:  1600Summary:  Atopic dermatitis (AD; also known as eczema) is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and has a relapsing course, often improving by adolescence, but sometimes persisting into (or first appearing in) adulthood or even old age.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: abrocitinib Alclometasone Amcinonide ApexiCon apremilast Atopic dermatitis Azasan Azathioprine baricitinib Betamethasone Clobetasol Clobex Clocortolone Cloderm Cordran corticosteroids crisaborole Cutivate Cyclosporine Source Type: research
More News: Allergy | Allergy & Immunology | Corticosteroid Therapy | Dermatitis | Dermatology